2026-07-05 · compounded semaglutide, compounded tirzepatide, GLP-1, FDA, 503A, 503B, pharmacy compounding, drug safety · 18 min read

Is compounded semaglutide still legal in 2026?

Only under narrow clinical-need exceptions. Semaglutide came off the FDA drug-shortage list on 2 October 2024 (FDA 2024 Semaglutide Shortage Resolution Notice), and tirzepatide followed on 19 December 2024 (FDA 2024 Tirzepatide Shortage Resolution Notice). Once a drug is no longer in shortage, Section 503A of the Federal Food, Drug and Cosmetic Act prohibits compounders from producing a copy that is essentially the same as the FDA-approved product. FDA 2025 guidance narrowly permits patient-specific 503A compounding when there is a documented allergy to an excipient in Ozempic or Wegovy, a dose not commercially available (for example, pediatric or renal), or a medically necessary combination product. Mass-produced telehealth-clinic 'generic semaglutide' does not qualify. Legal enforcement continued through 2025 in Outsourcing Facilities Association v. FDA, but the general trajectory is clear: FDA-approved product is the default, and compounded product is a narrow exception.

What was the sodium salt form warning about?

In June 2023 the FDA issued warning letters to compounding pharmacies producing semaglutide sodium and semaglutide acetate salt forms, stating explicitly that these are not the same active ingredient as the FDA-approved semaglutide base used in Ozempic, Wegovy, and Rybelsus. The efficacy and safety of the salt forms had not been evaluated in clinical trials, and no bioequivalence data existed. Some compounders were sourcing bulk semaglutide sodium from research-chemical suppliers with limited quality controls. The practical rule for a patient is to look at the pharmacy's product label: it should read semaglutide (base) with a mg-per-dose strength, not semaglutide sodium or semaglutide acetate. A product that does not clearly identify the base form is not appropriate, and the state board of pharmacy is the right channel for a complaint (FDA 2023 Warning Letters on Semaglutide Salt Forms).

What is the difference between 503A and 503B compounding?

Section 503A of the Federal Food, Drug and Cosmetic Act covers traditional patient-specific pharmacy compounding. A 503A pharmacy takes a valid individual prescription for a specific patient and prepares that dose. It is state-regulated through the state board of pharmacy, and quality varies widely across states and individual pharmacies. Section 503B covers outsourcing facilities that can compound in advance of specific prescriptions, typically for hospitals and clinics. 503B facilities register with the FDA, follow current Good Manufacturing Practice (cGMP) standards, and are FDA-inspected — a much smaller and more tightly regulated universe than 503A. During the 2022–2024 shortage window both routes were used for semaglutide and tirzepatide; after the shortage ended, both categories became subject to the essentially-a-copy prohibition except under narrow clinical-need exceptions (FDA 2025 Section 503A Guidance).

How do I evaluate a compounding pharmacy?

Five checks matter. First, verify state board of pharmacy licensure — current license in the state where the pharmacy operates and in the state where you live; most state boards publish a public license lookup. Second, insist on a patient-specific prescription from your clinician who has actually seen and evaluated you — not an online questionnaire scored by an algorithm and countersigned by a physician you never met. Third, check the product label: it should state semaglutide (base) or tirzepatide with a clear mg-per-dose strength, not semaglutide sodium or semaglutide acetate (FDA 2023). Fourth, dosing should be labelled in mg per dose with clear instructions, not only in IU/mL — dose-conversion errors have caused hospitalisations and at least one death (FDA 2024 Adverse Event Communication). Fifth, ask how the pharmacy supports MedWatch adverse-event reporting; a legitimate compounder can name the pathway (APhA 2024 Compounding Position Statement).

Can compounded semaglutide still be used for microdosing?

Microdosing — using sub-therapeutic weekly semaglutide or tirzepatide, typically 0.125 to 0.5 mg semaglutide equivalents, off-label for weight or metabolic goals — sits in regulatory grey area in 2026. Prescribing FDA-approved product off-label is legal in the United States, and a clinician can lawfully prescribe a 0.25 mg starter pen of Ozempic or Wegovy for a patient who never titrates past that dose. Compounding an essentially-a-copy sub-therapeutic dose from bulk API is a different question. Post-shortage, FDA 2025 guidance treats a compounded copy of the FDA-approved product for a purpose the FDA-approved product already covers as prohibited under Section 503A. A clinical-need exception is narrow — for example, a documented allergy to an Ozempic excipient. For readers considering microdosing, the safer path is a 0.25 mg starter pen of the FDA-approved product used off-label under prescriber supervision. See the microdosing guide for a fuller framing.

What happens if my telehealth clinic switches me from compounded to brand-name mid-treatment?

This became common through 2025 as compounders wound down semaglutide and tirzepatide programs. The dose-conversion step is where most transition problems happen. Compounded product is often labelled in mg/mL or IU/mL and delivered with a syringe, while FDA-approved product is labelled in mg per pen click. The clinician should provide an explicit dose match — for example, 1.7 mg weekly compounded semaglutide (base) maps to the 1.7 mg Wegovy weekly pen — and the transition week should not skip a dose. Expect insurance and prior-authorisation delays: Wegovy and Zepbound often require BMI documentation, prior weight-loss attempts, and a related-condition diagnosis. Cash-pay pathways from the manufacturers (Novo Nordisk direct-cash Wegovy near 500 US dollars per month in 2024, Lilly Direct for Zepbound single-dose vials) have narrowed the cost gap significantly since the compounding-was-common era. If your side effects change on the FDA-approved product, tell the prescriber — the excipients and delivery mechanism differ, and dose titration may need a brief step-down.

What are the cash-pay pathways for Wegovy and Zepbound in 2026?

The economics changed sharply in 2024 and 2025. Novo Nordisk launched a direct-cash pathway for Wegovy in 2024 pricing all monthly doses at roughly 500 US dollars for cash-pay patients — a meaningful drop from the 1300 US dollars list price. Eli Lilly's Lilly Direct offered Zepbound in single-dose vials at roughly 350 to 550 US dollars per month depending on strength, again for cash-pay patients through the manufacturer portal. Both programs require a valid US prescription; neither is available with insurance simultaneously. For patients who were on compounded semaglutide primarily for cost reasons, the direct-cash FDA-approved pathway now often costs less than the compounded product, without the sodium-salt-form, mislabelling, or dose-conversion risks. See the GLP-1 cost and insurance guide for the fuller 2026 pricing table.

How do I report an adverse event from a compounded GLP-1?

Three channels, and use them in parallel if the situation warrants. FDA MedWatch (1-800-FDA-1088 or the online reporting portal) is the federal adverse-event surveillance system for any drug product, including compounded ones — the FDA has explicitly asked patients and clinicians to report compounded-GLP-1 events. Poison Control (1-800-222-1222) is the immediate-guidance channel for a suspected overdose, unit-conversion error, or accidental pediatric ingestion, staffed 24 hours a day. The state board of pharmacy in the state where the pharmacy operates is the licensure-and-enforcement channel for suspected mislabelling, salt-form product, unlicensed physician oversight, or interstate compounding violations (NABP 2024 State Board Enforcement Actions Summary). For a life-threatening situation — severe pancreatitis, severe hypoglycaemia with unresponsiveness, or an acute allergic reaction — call 911 first, then file the reports.

Compounded Semaglutide and Tirzepatide in 2026: Safety, Legality, and Quality After the Shortage Ended

Compounded semaglutide and tirzepatide exploded during the 2022–2024 GLP-1 shortage, filled a real access gap for millions of US adults, and then became largely illegal on 2 October 2024 (FDA 2024 Semaglutide Shortage Resolution Notice) and 19 December 2024 (FDA 2024 Tirzepatide Shortage Resolution Notice) when the FDA declared both drugs no longer in shortage. The 2026 landscape is genuinely different from the compounding-was-normal era of 2023: Section 503A of the Federal Food, Drug and Cosmetic Act prohibits compounders from producing a copy that is essentially the same as the FDA-approved product once that product is no longer in shortage, and FDA 2025 guidance narrowed the clinical-need exceptions to documented allergy to an excipient, a dose not commercially available, or a medically necessary combination product.

The honest framing: compounded semaglutide and tirzepatide were a legitimate shortage-era response for a real access problem. They were also uneven in quality. Some compounders used the FDA-warned-against sodium salt form (FDA 2023 Warning Letters on Semaglutide Salt Forms), dosing was often expressed in unfamiliar units of IU/mL rather than mg per dose, and the FDA has documented multiple hospitalisations and at least one death attributed to compounded-product unit-conversion errors (FDA 2024 Adverse Event Communication on Compounded Semaglutide). The safest 2026 path is FDA-approved product from Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound. If compounding is being used, patient-specific 503A prescriptions from state-licensed pharmacies with clear mg-per-dose labelling — not online telehealth clinics selling generic-looking product — are the legitimate option.

Quick stats

• 2 October 2024 — FDA declared semaglutide no longer in shortage; 503A “essentially a copy” prohibition triggered for Ozempic and Wegovy compounded copies (FDA 2024 Semaglutide Shortage Resolution Notice).
• 19 December 2024 — FDA declared tirzepatide no longer in shortage; same trigger for Mounjaro and Zepbound compounded copies (FDA 2024 Tirzepatide Shortage Resolution Notice).
• June 2023 — FDA warning letters to compounders on semaglutide sodium and acetate salt forms — not the same active ingredient as FDA-approved semaglutide base (FDA 2023 Warning Letters).
• 3,000+ poison-control calls related to semaglutide from 2019 through 2023, a substantial fraction linked to compounded-product dosing errors (CDC 2024 Poison Control Reports on Compounded GLP-1s).
• 503A is state-regulated patient-specific compounding; 503B is FDA-regulated outsourcing-facility compounding — two different regulatory universes.
• 911 red flag — accidental 10× overdose or IU/mL versus mg dose-conversion confusion, severe pancreatitis, or acute allergic reaction.
• 1-800-222-1222 — US Poison Control for immediate guidance on a suspected compounded-product overdose or unit-conversion error.

The regulatory background you need to understand

Three product categories, three different rulebooks. Getting these straight is the difference between a legitimate 2026 prescription and a legally grey purchase.

How the shortage-and-resolution timeline unfolded

The dates matter — they determine what was legal when, and they explain why some compounders wound down programs in early 2025 while others continued under litigation.

What “compounded” actually means

Four points that most 2023-era readers never had to think about, and that matter more now.

Not a generic

FDA-approved semaglutide and tirzepatide are still under active US patent. There is no legal generic version of either drug in 2026. A pharmacy selling “generic semaglutide” is not offering a generic in the FDA-approved sense of the word — it is offering a compounded product, which is a regulatory category with a different rulebook and different quality-control standards. Salt forms (semaglutide sodium, semaglutide acetate) are not the same as the base form and are not covered by the FDA’s approval of Ozempic or Wegovy (FDA 2023 Warning Letters).

API sourcing variability

Compounded product is only as good as its active pharmaceutical ingredient (API). Some 503A pharmacies source semaglutide base from FDA-inspected foreign manufacturers with legitimate certificates of analysis; others source from research-chemical suppliers with limited or unverifiable quality controls. The variability is not visible to the patient at the point of sale. This is the single biggest quality question in the compounded-GLP-1 market, and it does not have a consumer-facing solution — the state board of pharmacy and the FDA are the enforcement mechanisms.

Dosing unit confusion

FDA-approved Ozempic and Wegovy dose in mg per pen click — the pen delivers a fixed volume at a fixed concentration, and the user does not have to do any conversion math. Compounded product is typically supplied as a vial with a concentration in mg/mL or IU/mL and a syringe. A patient who reads 250 IU on a syringe scale as 2.5 mg when the concentration actually makes it 0.25 mg has caused a 10× overdose. The FDA’s 2024 Adverse Event Communication documented multiple hospitalisations and at least one death from this exact conversion error.

Not the same as pharmaceutical-grade in a shortage-appropriate context

Even during the 2022–2024 shortage window when compounded product was broadly legal, adverse-event reporting was uneven, product labelling was inconsistent, and quality varied widely between pharmacies. The shortage-era permission to compound was a regulatory accommodation, not a statement that compounded product was equivalent to FDA-approved product on efficacy, safety, or quality. Any 2026 conversation about compounded GLP-1 should start from that baseline.

Clinical-need exceptions that remain legal in 2026

FDA 2025 Section 503A Guidance enumerated the narrow scenarios in which a 503A patient-specific compounded semaglutide or tirzepatide product remains legal after the shortage ended. These are the honest options for a patient with a genuine clinical reason to prefer compounded over FDA-approved product.

How to evaluate a compounding pharmacy

If a clinical-need exception applies and compounded product is being used, five checks separate a legitimate 503A pharmacy from a telehealth-storefront reseller.

1. State board of pharmacy licensure

Every US state has a board of pharmacy with a public license lookup. Verify current licensure in the state where the pharmacy operates and in the state where you receive shipments. Cross-state licensure is required; a pharmacy operating from Florida and shipping to Massachusetts must hold a non-resident Massachusetts pharmacy licence in addition to its Florida licence. Interstate-compounding enforcement actions were a major theme of 2024 and 2025 state board activity (NABP 2024 State Board of Pharmacy Enforcement Actions Summary).

2. Individual prescription from your prescribing clinician

Section 503A compounding is patient-specific by statute. A legitimate 503A prescription comes from a clinician who has actually seen and evaluated the patient — not from an online questionnaire scored by an algorithm and countersigned by a physician who never met the patient. The mass-market telehealth-clinic model in which one physician nominally supervises tens of thousands of prescriptions per month is not consistent with the traditional 503A framework (APhA 2024 Compounding Position Statement).

3. Ingredient identity — semaglutide (base), not sodium

Read the pharmacy’s product label. It should state semaglutide or semaglutide base with a strength in mg per dose or mg/mL. It should not state semaglutide sodium or semaglutide acetate — those are salt forms the FDA has explicitly warned against (FDA 2023 Warning Letters), with unknown efficacy and safety in humans. For tirzepatide, the label should state tirzepatide with a mg-per-dose strength. If the label is unclear, ask the pharmacy for a certificate of analysis and the API supplier’s identity.

4. Clear mg-per-dose labelling

The single biggest source of hospitalisation from compounded GLP-1 has been unit-conversion error. A legitimate compounding pharmacy labels a vial with both the concentration (mg/mL) and a clear weekly dose instruction in mg — for example, “draw 0.5 mg (0.2 mL of 2.5 mg/mL) once weekly.” An IU/mL-only label with no mg equivalent is not adequate; ask for a mg-per-dose reconstitution card or refuse the product (FDA 2024 Adverse Event Communication).

5. Adverse-event reporting pathway

A legitimate 503A pharmacy supports FDA MedWatch reporting for any adverse event and can name the reporting pathway. It also has a real address, a licensed pharmacist accessible by phone, and a state-board complaint process. A pharmacy that will not name its MedWatch pathway or its supervising pharmacist is not a pharmacy you should be using.

How the treatment landscape compares in 2026

Six categories, six different risk and access profiles. The table is the honest 2026 map.

Special-situation sections

The microdosing regulatory grey area

Microdosing — 0.125 to 0.5 mg semaglutide equivalents weekly, or the tirzepatide equivalent, off-label for weight or metabolic goals — was one of the largest growth areas for compounded product in 2023 and 2024. The 2026 legal picture is: prescribing FDA-approved product off-label is legal, so a clinician can prescribe a 0.25 mg Ozempic or Wegovy starter pen for a patient who never titrates past that dose. Compounding an essentially-a-copy sub-therapeutic dose from bulk API is a different question, and FDA 2025 guidance treats it as prohibited under Section 503A unless a clinical-need exception applies. The safer 2026 microdosing route is a starter-dose FDA-approved pen used off-label under prescriber supervision. See the GLP-1 microdosing guide for the fuller framing.

The sodium salt form issue

FDA 2023 Warning Letters to compounding pharmacies were explicit: semaglutide sodium and semaglutide acetate are not the same active ingredient as the FDA-approved semaglutide base in Ozempic, Wegovy, and Rybelsus. The salt forms were not evaluated in the STEP trials, and no bioequivalence data exist. Detection is a label check: the label should read semaglutide or semaglutide base with a mg-per-dose strength. A label that reads semaglutide sodium or semaglutide acetate is a product the FDA has explicitly warned against and should not be used. The state board of pharmacy is the appropriate complaint channel for a pharmacy dispensing salt-form product without disclosure.

Reporting an adverse event

Three channels, used in parallel where warranted. FDA MedWatch (1-800-FDA-1088 or the online reporting portal) is the federal adverse-event surveillance system and the FDA has explicitly asked patients and clinicians to report compounded-GLP-1 events. Poison Control (1-800-222-1222) provides immediate 24-hour guidance for a suspected overdose, unit-conversion error, or accidental pediatric ingestion. The state board of pharmacy in the state where the pharmacy operates is the licensure-and-enforcement channel for mislabelling, salt-form product, or unlicensed physician oversight (NABP 2024). For life-threatening events — severe pancreatitis, severe hypoglycaemia with unresponsiveness, or acute allergic reaction — 911 comes first, then the reports.

Cost math in 2026

The economics changed sharply. In 2023, list-price Wegovy at roughly 1,300 US dollars per month made compounded semaglutide at 150 to 250 US dollars a large cost gap. In 2024 Novo Nordisk launched a direct-cash pathway pricing Wegovy at roughly 500 US dollars per month for cash-pay patients, and Eli Lilly’s Lilly Direct offered single-dose Zepbound vials at 350 to 550 US dollars. For patients who were on compounded product primarily for cost reasons, the direct-cash FDA-approved pathway often now costs less than the compounded alternative — without the sodium-salt-form, mislabelling, or dose-conversion risks. See the GLP-1 cost and insurance guide for the fuller pricing table.

Cash-pay versus insurance

Cash-pay and insurance-covered are two different economics. Insurance-covered Wegovy or Zepbound requires prior authorisation, documented BMI, prior weight-loss attempts, and often a related-condition diagnosis; the copay is typically 25 to 100 US dollars per month once approved. Direct-cash Novo Nordisk Wegovy or Lilly Direct Zepbound cannot be combined with insurance and runs 350 to 550 US dollars per month, but requires no prior authorisation. For patients whose insurance covers weight-loss medication, insurance is almost always cheaper. For patients whose insurance excludes weight-loss medication — still common in employer plans as of 2026 — the direct-cash pathway has replaced most of the legitimate cost case for compounded product.

When your telehealth clinic switches from compounded to brand-name mid-treatment

This became common through 2025. The dose-conversion step is where transitions fail. Compounded product is typically labelled in mg/mL with a syringe; FDA-approved product is labelled in mg per pen click. A patient stable at 1.7 mg weekly compounded semaglutide should be switched to the 1.7 mg Wegovy weekly pen, not the 2.4 mg maintenance dose. The transition week should not skip a dose. Expect a brief GI-tolerability adjustment because the excipients and delivery mechanism differ; if side effects change materially, tell the prescriber and consider a step-down for one week. Prior-authorisation delays for insurance-covered Wegovy or Zepbound are common — ask the prescriber to submit the paperwork before the last compounded pen expires.

The state-board complaint pathway

If a compounder is dispensing salt-form product, mislabelling doses, operating without individual prescriptions, or shipping across state lines without non-resident licensure, the state board of pharmacy is the correct enforcement channel. Every state board has a public complaint portal. NABP’s 2024 enforcement-actions summary listed dozens of cases in California, Florida, Texas, Massachusetts, and New York against unlicensed telehealth-compounding operations. Filing a complaint does not require a lawyer, does not require the patient to prove injury, and can be filed anonymously in some states. For an adverse event and a suspected compounding violation, file the FDA MedWatch report and the state board complaint in parallel.

Red flags — when to see a doctor

Some findings are not routine and warrant immediate action.

• Accidental 10× overdose or IU-versus-mg unit-conversion confusion — call 911 and Poison Control 1-800-222-1222; the FDA has documented hospitalisations and at least one death from this exact error (FDA 2024 Adverse Event Communication).
• Persistent vomiting with severe upper-abdominal pain radiating to the back — pancreatitis workup; call 911 or go to the ER; class-labelled risk for all GLP-1 receptor agonists.
• Severe hypoglycaemia with confusion, seizure, or unresponsiveness — rare on GLP-1 alone, common when GLP-1 is combined with sulfonylurea or insulin — call 911; oral or IM glucagon if available.
• Acute allergic reaction — hives, tongue or throat swelling, difficulty breathing — call 911; anaphylaxis to compounded product excipients has been reported.
• New or worsening suicidal ideation — call 988 (US Suicide and Crisis Lifeline); mood signals across the GLP-1 class remain under postmarketing surveillance.
• Product label that does not clearly state semaglutide (base) or tirzepatide with a mg-per-dose strength — do not use the product; consult prescriber and file a state board of pharmacy complaint (FDA 2023 Warning Letters).

Bottom line

Compounded semaglutide and tirzepatide filled a real access gap during the 2022–2024 FDA-declared shortage, and the 503A and 503B compounding pathways are legitimate parts of the US pharmacy system. The 2026 picture is different from the 2023 picture in ways that matter: the shortages are over, the “essentially a copy” prohibition is in force under Section 503A, direct-cash Wegovy and Lilly Direct Zepbound have narrowed the cost gap, and the FDA has documented adverse events and salt-form-product problems in the compounded market. For most patients in 2026, FDA-approved product from Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound is the safest and often cheapest option. Where a clinical-need exception applies, a patient-specific 503A prescription from a state-licensed pharmacy with clear mg-per-dose labelling is the legitimate route. Online telehealth-clinic generic-looking product and research-chemical resellers are neither.

How this connects to the rest of the site

For the FDA-approved brand overviews and dosing detail, see Wegovy for weight loss, Ozempic for weight loss, Zepbound for weight loss, Mounjaro for weight loss, and Saxenda for weight loss. For the molecule-level context, see semaglutide for weight loss, tirzepatide for weight loss, and semaglutide versus tirzepatide. For head-to-head comparisons, see Ozempic versus Wegovy and GLP-1 medications compared. For cost, coverage, and the direct-cash pathways, see GLP-1 cost and insurance. For microdosing and off-label practice, see GLP-1 microdosing and GLP-1 weight loss overview. For the discontinuation and regain framework, see rebound weight gain after stopping GLP-1. For class-wide safety framing, see weight loss drug safety.

Compounded semaglutide and tirzepatide FAQ

Is compounded semaglutide still legal in 2026? Only under narrow clinical-need exceptions per FDA 2025 Section 503A Guidance — documented allergy, unavailable dose, or medically necessary combination.

What is the sodium salt form issue? FDA 2023 Warning Letters — semaglutide sodium and acetate are not the same active ingredient as FDA-approved semaglutide base; do not use.

503A versus 503B? 503A is state-regulated patient-specific compounding; 503B is FDA-regulated outsourcing-facility compounding.

How do I evaluate a compounding pharmacy? State board of pharmacy licence, patient-specific prescription, semaglutide (base) not sodium, mg-per-dose labelling, MedWatch pathway.

Can I still microdose? Off-label prescribing of FDA-approved product remains legal; compounding an essentially-a-copy microdose is now regulatory grey area — see the microdosing guide.

What if my telehealth clinic switches me to brand-name? Match the mg dose precisely; do not skip the transition week; expect brief GI-tolerability adjustment; ask about prior authorisation.

What are the cash-pay pathways? Novo Nordisk direct-cash Wegovy near 500 US dollars per month; Lilly Direct Zepbound single-dose vials at roughly 350 to 550 US dollars per month.

How do I report an adverse event? FDA MedWatch 1-800-FDA-1088; Poison Control 1-800-222-1222; state board of pharmacy for licensure violations; 911 for life-threatening events.